Monoclonal antibody

Gene Therapy Market Overview: Forecast Market Size, Major Driver, Key Trends And Largest Region - By The Business Research Company

Retrieved on: 
Monday, April 10, 2023
Monoclonal antibody, Cell death, Gene, Gene editing, Cancer, Research, TESSA, Death, Investment, Growth, American Cancer Society, Autoimmunity, Vaccine

LONDON, April 10, 2023 /PRNewswire/ -- As per The Business Research Company's Gene Therapy Global Market Report 2023, the global gene therapy market size will grow from $7.3 billion in 2022 to $9.4 billion in 2023 at a compound annual growth rate (CAGR) of more than 27%. The gene therapy market share is then expected to grow from $24 billion in 2027 at a CAGR of more than 26%.

Key Points: 
  • The gene therapy market share is then expected to grow from $24 billion in 2027 at a CAGR of more than 26%.
  • Increasing number of cancer cases is expected to drive the growth of the gene therapy market during the forecast period.
  • Cancer gene therapy is an emerging field using genetic material to modify cells in vitro or in vivo to help effect a cure.
  • As per the gene therapy market forecast, North America was the largest region in the gene therapy market, accounting for 44.6% of the global market in 2022.

Gene Therapy Market Overview: Forecast Market Size, Major Driver, Key Trends And Largest Region - By The Business Research Company

Retrieved on: 
Monday, April 10, 2023
Monoclonal antibody, Cell death, Gene, Gene editing, Cancer, Research, TESSA, Death, Investment, Growth, American Cancer Society, Autoimmunity, Vaccine

LONDON , April 10, 2023 /PRNewswire/ -- As per The Business Research Company's Gene Therapy Global Market Report 2023, the global gene therapy market size will grow from $7.3 billion in 2022 to $9.4 billion in 2023 at a compound annual growth rate (CAGR) of more than 27%. The gene therapy market share is then expected to grow from $24 billion in 2027 at a CAGR of more than 26%.

Key Points: 
  • The gene therapy market share is then expected to grow from $24 billion in 2027 at a CAGR of more than 26%.
  • Increasing number of cancer cases is expected to drive the growth of the gene therapy market during the forecast period.
  • Cancer gene therapy is an emerging field using genetic material to modify cells in vitro or in vivo to help effect a cure.
  • As per the gene therapy market forecast, North America was the largest region in the gene therapy market, accounting for 44.6% of the global market in 2022.

EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress

Retrieved on: 
Wednesday, March 22, 2023
Monoclonal antibody, Lymphoid leukemia, CD2, Immunology, Therapy, CD3, CD28, CD20, Neoplasm, Cancer, Research, Immunotherapy, Acute myeloid leukemia, CD8, Festival, Lymphocyte, EVOLVE, Pharmaceutical industry, Vaccine

BRANFORD, Conn., March 22, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced that new preclinical data on EVOLVE™, the company’s novel costimulatory T cell engager platform, were featured in an oral presentation at the Festival of Biologics Immunotherapy World Congress. The presentation highlighted the potential of the company’s innovative integrated CD2 costimulatory strategy to overcome treatment limitations of current immunotherapies. Additionally, the company disclosed the first data for EVOLVE-105, its best-in-class CD20xCD3 multispecific T cell engager that also selectively mediates CD2 costimulation.

Key Points: 
  • The presentation highlighted the potential of the company’s innovative integrated CD2 costimulatory strategy to overcome treatment limitations of current immunotherapies.
  • Additionally, the company disclosed the first data for EVOLVE-105, its best-in-class CD20xCD3 multispecific T cell engager that also selectively mediates CD2 costimulation.
  • Moreover, they do not provide coordinated costimulatory receptor activation to overcome T cell dysfunction and drive more effective and longer lasting anti-tumor responses.
  • The Festival of Biologics presentation, entitled, “A novel costimulatory T cell engager platform engineered for the treatment of immune suppressive tumors,” included key new findings for the company’s EVOLVE platform and its growing costimulatory T cell engager portfolio.

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas

Retrieved on: 
Monday, March 20, 2023
Bispecific monoclonal antibody, Pancreatic cancer, CD47, Macrophage, ADCC, ODD, Monoclonal antibody, RECIST, Pharmacokinetics, NK, Trial of the century, APC, Patient, ECOG, SAN, Cancer, ADCP, Neoplasm, Ageing, FDA, Therapy, Safety, Pharmaceutical industry

PT886 was assembled using Phanes' proprietary bispecific antibody platforms PACbody™ and SPECpair™ and was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA last year.

Key Points: 
  • PT886 was assembled using Phanes' proprietary bispecific antibody platforms PACbody™ and SPECpair™ and was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA last year.
  • The anti-CD47 arm of PT886 is highly differentiated and has demonstrated minimum binding to human red blood cells while maintains strong binding activity to CD47 on tumor cells.
  • "PT886 targets a validated tumor associated antigen in claudin 18.2 with enhanced anti-tumor activity and broadened tumor killing spectrum through a best-in-class anti-CD47 arm.
  • It is a product of Phanes' ingenious innovation in creative design of both novel therapeutic approaches and practical technologies," said Dr. Ming Wang, Founder and CEO of Phanes Therapeutics.

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022

Retrieved on: 
Thursday, March 9, 2023
Biotechnology, Pharmaceutical, Health, PD-1, Prostate cancer, Amgen, Research, Compugen (company), Sale, Patient, GSK, Rights, Collaboration, Stanford University School of Medicine, Senior, EPIX, MD, Webcast, Lung cancer, Interest, BTK, Entrepreneurship, Monoclonal antibody, US Foods, Hematological Cancer Research Investment and Education Act, VEGF, Executive, NSCLC, Immunotherapy, FDA, Panitumumab, Knowledge, R, Doctor of Philosophy, Colorectal cancer, SMMT, Celera Corporation, Crown Bioscience International, Biogen, Communication, Roche, Therapy, Quality of life, CMO, Pharmaceutical industry, Security (finance), Cryptocurrency, Management, Bayer, Pharmacyclics

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December 31, 2022.
  • Summit is initiating development activities for SMT112 and will do so first in non-small cell lung cancer (NSCLC) indications.
  • Summit intends to start treating patients in clinical studies during the second quarter of 2023.
  • Summit’s management team will host an earnings call to discuss its fourth quarter 2022 financial results and provide an operational update for the Company today, March 9, 2023, at 9:00am ET.

2023 Annual Next-Gen Immuno-Oncology Congress: Addressing the Challenges and Future Directions in IO Research (Boston, MA, United States - June 22-23, 2023)

Retrieved on: 
Thursday, March 9, 2023
ADC, Inhibitor, Conference, Research, Monoclonal antibody, Congress, Hook effect, Biotechnology, Immunotherapy, Antibody, Vaccine, Video game, Pharmaceutical industry, IO

DUBLIN, March 9, 2023 /PRNewswire/ -- The "6th Annual Next-Gen Immuno-Oncology Conference" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 9, 2023 /PRNewswire/ -- The "6th Annual Next-Gen Immuno-Oncology Conference" conference has been added to ResearchAndMarkets.com's offering.
  • The 6th Annual Next Gen Immuno-Oncology Conference to be held on 22nd - 23rd June 2023, in Boston, would address the challenges and future directions in IO research.
  • This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development, and personalized immunotherapy.
  • Keynote presentations, Brainstorming Panel Discussions, and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of First-in-Class Anti-CD39xTGF-β Bispecific Antibody ES014

Retrieved on: 
Monday, February 27, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, Cancer, ATP, Monoclonal antibody, PD-1, Adenosine, Ascites, Pleural effusion, Patient, Trial of the century, TGF, TME, CD39, Medical imaging, Vaccine

Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide, today announced that the first patient has been dosed in a Phase 1 clinical trial of ES014, a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb).

Key Points: 
  • Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide, today announced that the first patient has been dosed in a Phase 1 clinical trial of ES014, a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb).
  • ES014 simultaneously targets the CD39-adenosine and TGF-β pathways, aiming to convert the immunosuppressive tumor microenvironment (TME) into an immune-friendly one.
  • ES014 simultaneously neutralizes TGF-β, leading to activation of T cells and blockade of Treg differentiation while avoiding or minimizing systemic immunotoxicity.
  • I am excited to move ES014 now to clinical study to investigate its safety and preliminary clinical signal in human,” shared Professor Lu.

Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

Retrieved on: 
Friday, February 17, 2023
Completeness, AML, Stanford University, Transplant, Biomarker, HCT, TBI, Șaeș, GVHD, Patient, Incidence, Skin, Chimera, Mortality, Therapy, Risk, Graft-versus-host disease, Monoclonal antibody, Toxic epidermal necrolysis, HSC, Key finding attacks, MDS, Acute myeloid leukemia, Broder, CD117, Syndrome, Rare, Vaccine, Pharmaceutical industry, Jasper

The data are being featured in two oral presentations and one poster presentation at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (February 15-19, 2023; Orlando, Florida).

Key Points: 
  • The data are being featured in two oral presentations and one poster presentation at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (February 15-19, 2023; Orlando, Florida).
  • The presentations further support the differentiated clinical profile of briquilimab and its potential as a safe and efficacious conditioning agent for HCT therapies.
  • Specifically, the data show that a conditioning regimen of briquilimab plus Flu/TBI led to successful engraftment of donor blood stem cells in the patients treated.
  • The conditioning regimen was well-tolerated, with no infusion toxicities observed and no briquilimab-related serious adverse events (SAEs).

LifeArc Ventures - strong performance in 2022 & sustained investment in innovation

Retrieved on: 
Wednesday, February 1, 2023
CMO, Science, Lead, LifeArc, Antibody, Investment, Viral, System, Biotechnology, Patient, News, Atopic dermatitis, Monoclonal antibody, Risk, Death, Growth, Public, AstraZeneca, DJS, AbbVie, Association of British HealthTech Industries, Vaccine, Pharmaceutical industry, COVID-19

LONDON, Feb. 1, 2023 /PRNewswire/ -- LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, today provides an update on its portfolio.

Key Points: 
  • "We pride ourselves on the hands-on support we give our portfolio companies, offering strategic, practical and scientific guidance as well as funding.
  • We believe the award for LifeArc recognises the unique combination of skills and expertise that LifeArc and LifeArc Ventures provide to support and promote life changing science.
  • You can now follow us on our dedicated LinkedIn page and Twitter, and on our upcoming new LifeArc Ventures website.
  • We're open to new opportunities and welcome introductions, so please get in touch if you think we can help.

LifeArc Ventures - strong performance in 2022 & sustained investment in innovation

Retrieved on: 
Wednesday, February 1, 2023
CMO, Science, Lead, LifeArc, Antibody, Investment, Viral, System, Biotechnology, Patient, News, Atopic dermatitis, Monoclonal antibody, Risk, Death, Growth, Public, AstraZeneca, DJS, AbbVie, Association of British HealthTech Industries, Vaccine, Pharmaceutical industry, COVID-19

LONDON, Feb. 1, 2023 /PRNewswire/ -- LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, today provides an update on its portfolio.

Key Points: 
  • "We pride ourselves on the hands-on support we give our portfolio companies, offering strategic, practical and scientific guidance as well as funding.
  • We believe the award for LifeArc recognises the unique combination of skills and expertise that LifeArc and LifeArc Ventures provide to support and promote life changing science.
  • You can now follow us on our dedicated LinkedIn page and Twitter, and on our upcoming new LifeArc Ventures website.
  • We're open to new opportunities and welcome introductions, so please get in touch if you think we can help.